A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study of the Safety, Tolerability and Ability of CMX001 to Prevent or Control CMV Infection in R+ Hematopoietic Stem Cell Transplant Recipients.

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study of the Safety, Tolerability and Ability of CMX001 to Prevent or Control CMV Infection in R+ Hematopoietic Stem Cell Transplant Recipients.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2016

At a glance

  • Drugs Brincidofovir (Primary)
  • Indications Cytomegalic inclusion disorders; Cytomegalovirus infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Chimerix
  • Most Recent Events

    • 03 Mar 2016 Results (analysis of cytomegalovirus DNA polymerase gene mutations) published in the Journal of Infectious Diseases.
    • 08 Sep 2014 Results published in the Media Release.
    • 24 Mar 2014 Results were presented at the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in April 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top